Partnership to End Hiv, Aids & Hepatitis

Coalition of non-profit organizations supporting funding and access to HIV/AIDS treatments

Based in FL

🤖

AI Overview

With $620K in lobbying spend across 16 quarterly filings, Partnership to End Hiv, Aids & Hepatitis is an active lobbying client. Their lobbying covers 1 issue area. Active from 2022 to 2025.

$620K

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2022	$160K
2023	$150K
2024	$160K
2025	$150K

Issues Lobbied

Health Issues

Lobbying Firms

Kelley Drye & Warren LLP

Lobbyists

Mark Anderson Scott Mcgee Dana Wood Laurie Rubiner

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues

•Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support.

•H.R. 8295, FY23 Labor HHS Appropriations bill, provisions related to Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support.

•H.R. 8295, FY23 Labor HHS Appropriations bill, provisions related to Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support; Federal Policy and Congress

•H.R. 2617, the FY23 Consolidated Appropriations Act, provisions related to Federal funding and expanded access to pre-exposure prophylaxis (PrEP) medications and related support; Federal Policy and Co

•FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (draft bill); provisions related to funding for Ending the HIV Epidemic Initiative, Ryan Wh